Calculus Capital invests in Collagen Solutions

Private equity fund manager Calculus Capital has participated in a £6million investment in Collagen Solutions, a leading biomaterials company developing and manufacturing medical grade collagen components for use in regenerative medicine, medical devices and in vitro diagnostic products.

science labHeadquartered in Glasgow, Collagen Solutions has R&D and sales capabilities in San Jose, California and has recently acquired sourcing and manufacturing facilities in New Zealand. Collagen Solution’s customers range from research organisations to multi-national corporates.

The company is at the forefront of innovation in collagen production, as well as being intrinsically involved with customer R&D and academic research in San Jose. As part of the strategy to extend this market-leading knowledge, the company recently appointed Professor Robert Brown of UCL, as scientific adviser, renowned in the field of regenerative medicine.

Collagen Solutions raised £6m – part of which was used to fund the acquisition of Southern Light Biomaterials, a profitable business converting collagen and other biological materials into value added products. Other funds were raised to allow the Company to advance operational projects and further expand its sales and marketing efforts. Collagen Solutions relisted on AIM on 10 December 2014 as part of the transaction.

Rick Jones, Investment Director, Calculus Capital said: “Calculus has a long track record in the healthcare space and we are delighted to back Stewart and the team at Collagen Solutions. The company has a strong position in a high growth market and we are pleased to support it in the important work that it does.”

Stewart White, Chief Executive of Collagen Solutions, said: “Calculus is well known to members of the team at Collagen Solutions and we are pleased to welcome Calculus as an investor as we embark on the next stage of our growth. This represents a very significant step in completing the strategic aim of having a market capitalisation for the company of £100m by 2020.”